AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04432467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT04432467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT00264095 — intervention group
Intervention type: PROCEDURE
Intervention: Oncological surgery
Description: surgery is primary observed intervention and blood loss is between 500-3000 ml
Study NCT00408291 — intervention group
Intervention type: PROCEDURE
Intervention: Winsta PH osteosynthesis device
Description: The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
Study NCT01980225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collapse
Description: inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
Study NCT06031376 — intervention group
Intervention type: DRUG
Intervention: Fruquintinib
Description: 5mg once daily for 14 days on/7 days off, over a 21-day cycle
Study NCT06031376 — intervention group
Intervention type: DRUG
Intervention: PD-1 inhibitors
Description: The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
Study NCT06031376 — intervention group
Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Study NCT06031376 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
Study NCT00927329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dust mite inhalation
Description: Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
Study NCT02069249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sleep intervention
Description: Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
Study NCT02937272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered intravenously
Study NCT02937272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study NCT02937272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Administered intravenously
Study NCT02937272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study NCT02937272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Study NCT02069249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition intervention
Description: Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
Study NCT04176536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: Capsules
Study NCT03215667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft CLASSIC (beta-Tricalcium Phosphate)
Description: easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
Study NCT02655406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Class 2 compression stockings
Study NCT01569997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MultiDisciplinary Team Meetings (MDTM)
Description: The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
Study NCT04289194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCR040 (Phase 1)
Description: (Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
Study NCT04289194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Phase 2)
Description: (Phase 2) Intravenous administration of vehicle solution
Study NCT04289194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCR040 (Phase 2)
Description: (Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
Study NCT00374036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC
Description: capecitabine
Study NCT00374036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan
Study NCT02475629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibalizumab
Description: 2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
Study NCT02475629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
Study NCT03907813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: liposomal bupivacaine wound infiltration
Study NCT03907813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infiltration
Description: saline wound infiltration
Study NCT02225236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom Intervention
Study NCT03676205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Platelet-Rich Plasma
Study NCT03676205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traumeel
Description: Homeophatic Treatment
Study NCT00928512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinmab
Description: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
Study NCT00928512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
Study NCT02732223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional treatment
Description: Omega 3 fatty acids, plant sterols and polyphenols
Study NCT02732223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment
Description: placebo supplements
Study NCT04083794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory based assessments
Description: physical maneuvers to assess physiological responses in bone blood flow
Study NCT02110654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT02110654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT00827632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Study NCT04070235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229 tablets
Description: SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
Study NCT04070235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Study NCT04137016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Study NCT03579927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT03579927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT03579927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03579927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03579927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT03503344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO, 240 mg per day (4 x 60mg tablets)
Study NCT03503344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO, 240 mg per day (4 x 60mg tablets)
Study NCT02110654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Study NCT03579927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT03579927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03579927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-derived Natural Killer Cells
Description: Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
Study NCT04592835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites
Study NCT03527381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
Study NCT03527381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPB
Description: Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
Study NCT01120509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.
Study NCT00529282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole Medocaril
Description: 500 mg every 8 hours
Study NCT00529282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime with or without vancomycin
Description: 120-minute infusion \[250 mL\]
Study NCT02244307 — intervention group
Intervention type: DRUG
Intervention: alpha-adrenergic blocker
Study NCT04664712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused shock wave
Description: We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
Study NCT03503344 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05449912 — intervention group
Intervention type: OTHER
Intervention: Collection of environmental exposure data
Description: noise pollution air pollution proximity and accessibility to green spaces, blue spaces
Study NCT02742233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment
Study NCT02742233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment
Study NCT04536935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 1
Description: Free mobile mental health application that focuses on meditation
Study NCT04536935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 2
Description: Free mobile mental health application that assists with coping with COVID-19
Study NCT04536935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 3
Description: Free mobile mental health application that focuses on positive psychology.
Study NCT04536935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 4
Description: Free mobile application that addresses mental health issues through mood tracking
Study NCT00867997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoactive (remineralizing, neuroactive) dentifrice treatment
Description: Chemoactive (remineralizing, neuroactive) dentifrice treatment
Study NCT00867997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F
Description: Self-etch DBA followed by a hydrophobic resin layer
Study NCT00867997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil S3 Bond; Premise Flowable resin-based composite
Description: Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
Study NCT04049110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
Study NCT04049110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
Study NCT01704794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid + Paludrine + Jobelyn (500mg)
Description: Combination of routine drugs + Jobelyn
Study NCT01704794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid + Paludrine + Jobelyn (250mg)
Description: Standard routine drugs for treatment of SCD with 250mg Jobelyn
Study NCT01098331 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Prostatectomy
Study NCT01098331 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brachytherapy
Study NCT03933683 — intervention group
Intervention type: DEVICE
Intervention: Pudendal nerve terminal motor latency assessment
Description: After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
Study NCT03215628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCEUS
Description: Intravenous sulphur hexafluoride microbubbles
Study NCT03215628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCEUS
Description: Intravenous sulphur hexafluoride microbubbles
Study NCT03443856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
Study NCT03443856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chemotherapy
Description: Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
Study NCT01580709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple brushings
Description: Seven consecutive brush samples for cytology.
Study NCT01580709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodality tissue sampling
Description: Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
Study NCT01008761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
Study NCT01008761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suspension Placebo
Description: Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
Study NCT01506635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Study NCT01506635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: artificial tear twice a day
Study NCT02346227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AV2
Description: The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution.
Study NCT02346227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix.
Study NCT04047615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
Study NCT03423238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
Study NCT03423238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.